

“Comment on: Pulmonary hypertension screening in Children with sickle cell disease”

Riteeka Kumari Bhimani¹, * Deepak¹, and Mahima Khatri Mahima Khatri²

¹Shaheed Mohtarma Benazir Bhutto Medical College

²Dow University of Health Sciences Institute of Business and Health Management

July 31, 2023

”Comment on: Pulmonary hypertension screening in Children with sickle cell disease”

Riteeka Kumari Bhimani^{1*}, Deepak ¹, Mahima Khatri ²

¹ Shaheed Mohtarma Benazir Bhutto Medical College, Karachi, Pakistan

² Dow University Of Health Sciences, Karachi, Pakistan

Corresponding author: 1: Riteeka Kumari Bhimani

Contact: +923322667920

Email: riteekabhimani@gmail.com

Address : Flat no. PH1, 7th floor, Al medina center, D street, Upper Gizri, Karachi, Pakistan

Institute : Shaheed Mohtarma Benazir Bhutto Medical College, Karachi, Pakistan

ORCID: 0009-0003-5775-0777

Article type: Letter to the Editor

Word Count: 289

Key Words: Hemoglobinopathies, Sickle cell anemia, Hemolytic Anemia

Tables: None

Figures: None

Conflict of interest : None

Declaration: None

Acknowledgement: None

To The Editor ,

We have read the article “Pulmonary hypertension screening in Children with sickle cell disease” by Kok Hoe Chan et al.¹ with great interest and the work done by the authors is highly commendable. The article’s concluding point is that in children with SCD, PHT symptoms are inconsistent with ECHO, NT-proBNP, or BNP outcomes. Children using hydroxyurea have a low incidence of PHT based on TRV, hence screening may not be recommended for this demographic. However, it would be an honor to draw your attention to a few concerns that we possess.

Firstly, the author refrained from mentioning the impact of certain genes on pulmonary hypertension in sickle cell disease as mentioned in a study conducted in 2016² which shows a decreased expression of the MAPK8 gene contributes to the pathogenic progression of precapillary pulmonary hypertension in SCD patients, and single nucleotide polymorphisms in ADRB1, ACVRL1, and BMP6 associated with PHT in patients with SCD.³

Second, the essential elements of the pathophysiology underlying vaso-occlusive crises and pulmonary hypertension in SCD patients are hemolysis and nitric oxide deficiency, both of which are significant in disrupting endothelium, endothelial proliferation, and platelet activation, they have not been highlighted in this study.³

Moreover, considering the fact that the author has highlighted the crucial PHT biomarkers NT-proBNP, BNP, and ECHO, a study conducted in 2020 reveals additional potential biomarkers, such as Factor-15 (GDF-15), a cytokine overexpressed in hypoxic conditions including PHT, and superoxide dismutase, a mitochondrial enzyme also upregulated in PHT, can also be utilized for diagnosing PHT in patients with SCD.⁴

Lastly, the administration of vasodilators, oxygen therapy, iron chelation, and stem cell transplant are among the treatments for PHT that the author could have discussed for a better understanding of the topic.⁵

References:

1. Chan KH, Rizvi SH, De Jesus-Rojas W, et al. Pulmonary hypertension screening in children with sickle cell disease. *Pediatr Blood Cancer* . 2023;70(1):e29980. doi:10.1002/pbc.29980
2. Gordeuk VR, Castro OL, Machado RF. Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. *Blood* . 2016;127(7):820-828. doi:10.1182/blood-2015-08-618561
3. Shilo NR, Morris CR. Pathways to pulmonary hypertension in sickle cell disease: the search for prevention and early intervention. *Expert Rev Hematol* . 2017;10(10):875-890. doi:10.1080/17474086.2017.1364989
4. Sheikh AB, Nasrullah A, Lopez ED, et al. Sickle Cell Disease-Induced Pulmonary Hypertension: A Review of Pathophysiology, Management, and Current Literature. *Pulse (Basel)* . 2021;9(3-4):57-63. Published 2021 Sep 23. doi:10.1159/000519101
5. Willen SM, Gladwin MT. What is the role of screening for pulmonary hypertension in adults and children with sickle cell disease?. *Hematology Am Soc Hematol Educ Program* . 2017;2017(1):431-434. doi:10.1182/asheducation-2017.1.431